Citations

Clear

3138 citation(s) found for "Smith, AM".

S1‐03‐02: Cognitive Training
Smith, Glenn E.

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_2 | Pages: No page available

10.1016/j.jalz.2011.05.209 Get It

IC‐P‐017: Multimodality imaging differentiates dementia with lewy bodies from Alzheimer's disease
Lowe, Val J. , Weigand, Stephen D. , Przybelski, Scott A. , Preboske, Gregory M., Petersen, Ronald C. , Kantarci, Kejal , Boeve, Bradley F. , Senjem, Matthew L. , Knopman, David S. , Smith, Glenn E. , Ferman, Tanis J. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_1 | Pages: No page available

10.1016/j.jalz.2011.05.034 Get It

P1‐458: Differential association of memory endophenotypes to APOE alleles
Pedraza, Otto , Allen, Mariet , Ivnik, Robert J., Graff‐Radford, Neill R. , Roberts, Rosebud O., Petersen, Ronald C. , Younkin, Steven G., Ertekin‐Taner, Nilüfer , Crook, Julia E. , Smith, Glenn E. , Knopman, David S. , Pankratz, V. Shane

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_7 | Pages: No page available

10.1016/j.jalz.2011.05.740 Get It

Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997
Smith, Mitchell R. , Flinn, Ian W. , Grever, Michael R. , Rowe, Jacob M. , Dewald, Gordon W., Bennett, John M. , Paietta, Elisabeth , Byrd, John C., Hussein, Mohamad A., Appelbaum, Frederick R. , Larson, Richard A. , Litzow, Mark R. , Tallman, Martin S. , Byrd, John C. , Neuberg, Donna , Lazarus, Hillard M. , Larson, Richard A , Flinn, Ian W , Byrd, John C

Mayo Clinic

Blood | July 30, 2011 | Volume: 118 | Issue: 13 | Pages: 3525-3527

10.1182/blood-2011-03-342485 | PMID 21803850 Get It

Abstract Chemotherapy-related myeloid neoplasia (t-MN) is a significant late toxicity concern after cancer therapy. In the randomized intergroup phase 3 E2997 trial, initial therapy of chronic lymphocytic leukemia with fludarabine plus cyclophosphamide (FC) compared with fludarabine alone yielded higher complete and overall response rates and longer progression-free, but not overall, survival. Here, we report t-MN incidence in 278 patients enrolled in E2997 with a median 6.4-year follow-up. Thirteen cases (4.7%) of t-MN occurred at a median of 5 years from initial therapy for chronic lymphocytic leukemia, 9 after FC and 4 after fludarabine alone. By cumulative incidence methodology, rates of t-MN at 7 years were 8.2% after FC and 4.6% after fludarabine alone (P = .09). Seven of the 9 cases of t-MN after FC occurred without additional therapy. Abnormalities involving chromosomes 5 or 7 were found in 10 cases, which suggests alkylator involvement. These data suggest that FC may induce more t-MN than fludarabine alone.
Effects of 100 and 300 Units of Onabotulinum Toxin A on Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Phase II Randomized Clinical Trial
Crawford, E. David , Hirst, Kathryn , Kusek, John W., Donnell, Robert F., Kaplan, Steven A. , McVary, Kevin T. , Mynderse, Lance A. , Roehrborn, Claus G. , Smith, Christopher P. , Bruskewitz, Reginald C.

Mayo Clinic

Journal of Urology | July 27, 2011 | Volume: 186 | Issue: 3 | Pages: 965-970

10.1016/j.juro.2011.04.062 | PMID 21791356 Get It

Comparison of Maternal Milk (Breastmilk) Expression Methods in an African Nursery
Slusher, Tina M. , Slusher, Ida L., Curtis, Beverly, Smith, E. Alistair, Orodriyo, Elizabeth, Awori, Sussane, Nakakeeto, Margaret, Keating, Elizabeth M.

Mayo Clinic

Breastfeeding Medicine | July 8, 2011 | Volume: 7 | Issue: 2 | Pages: 107-111

10.1089/bfm.2011.0008 | PMID 21740276 Get It

Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization
Dai, Haiming , Smith, Alyson , Meng, X. Wei, Schneider, Paula A., Pang, Yuan‐Ping , Kaufmann, Scott H. , Kaufmann, Scott H , Pang, Yuan-Ping , Dai, Haiming

Mayo Clinic

Journal of Cell Biology | July 4, 2011 | Volume: 194 | Issue: 1 | Pages: 39-48

10.1083/jcb.201102027 | PMID 21727192 Get It

The mechanism by which the proapoptotic Bcl-2 family members Bax and Bak release cytochrome c from mitochondria is incompletely understood. In this paper, we show that activator BH3-only proteins bind tightly but transiently to the Bak hydrophobic BH3-binding groove to induce Bak oligomerization, liposome permeabilization, mitochondrial cytochrome c release, and cell death. Analysis by surface plasmon resonance indicated that the initial binding of BH3-only proteins to Bak occurred with similar kinetics with or without detergent or mitochondrial lipids, but these reagents increase the strength of the Bak–BH3-only protein interaction. Point mutations in Bak and reciprocal mutations in the BH3-only proteins not only confirmed the identity of the interacting residues at the Bak–BH3-only protein interface but also demonstrated specificity of complex formation in vitro and in a cellular context. These observations indicate that transient protein–protein interactions involving the Bak BH3-binding groove initiate Bak oligomerization and activation.
Classification of Benign Vascular Lesions: History, Current Nomenclature, and Suggestions for Imagers
Kransdorf, Mark J. , Murphey, Mark D. , Fanburg–Smith, Julie C.

Mayo Clinic

American Journal of Roentgenology | July 1, 2011 | Volume: 197 | Issue: 1 | Pages: 8-11

10.2214/ajr.10.5962 | PMID 21701004 Get It

Activation of Peroxisome Proliferator-Activated Receptor–δ Enhances Regenerative Capacity of Human Endothelial Progenitor Cells by Stimulating Biosynthesis of Tetrahydrobiopterin
He, Tongrong , Lü, Tong , Katušić, Zvonimir S. , Smith, Leslie , Joyner, Michael J. , Lu, Tong

Mayo Clinic

Hypertension | June 28, 2011 | Volume: 58 | Issue: 2 | Pages: 287-294

10.1161/hypertensionaha.111.172189 | PMID 21709207 Get It

The mechanisms underlying the regenerative capacity of endothelial progenitor cells (EPCs) are not fully understood. We hypothesized that biosynthesis of tetrahydrobiopterin is an important mechanism responsible for the stimulatory effects of peroxisome proliferator-activated receptor–δ (PPARδ) activation on regenerative function of human EPCs. Treatment of human EPCs with a selective PPARδ agonist GW501516 for 24 hours increased the levels of mRNA, protein, and enzymatic activity of GTP cyclohydrolase I (GTPCH I), as well as the production of tetrahydrobiopterin. The effects of GW501516 were mediated by suppression of PTEN expression, thereby increasing phosphorylation of AKT. The AKT signaling also mediated GW501516-induced phosphorylation of endothelial NO synthase. In addition, activation of PPARδ significantly enhanced proliferation of EPCs. This effect was abolished by the GTPCH I inhibitor, 2,4-diamino-6-hydroxypyrimidine, or genetic inactivation of GTPCH I with small interfering RNA but not by inhibition of endothelial NO synthase with N G -nitro- l -arginine methyl ester. Supplementation of NO did not reverse 2,4-diamino-6-hydroxypyrimidine-inhibited 5-bromodeoxyuridine incorporation. Furthermore, transplantation of human EPCs stimulated re-endothelialization in a mouse model of carotid artery injury. Pretreatment of EPCs with GW501516 significantly enhanced the ability of transplanted EPCs to repair denuded endothelium. GTPCH I-small interfering RNA transfection significantly inhibited in vivo regenerative capacity of EPCs stimulated with GW501516. Thus, in human EPCs, activation of PPARδ stimulates expression and activity of GTPCH I and biosynthesis of tetrahydrobiopterin via PTEN-AKT signaling pathway. This effect enhances the regenerative function of EPCs.
Clinical Stroke Trials
Brott, Thomas, Kothari, Rashmi, Smith, Wade S. , Goldstein, Larry B.

Mayo Clinic

Stroke | June 17, 2011 | Volume: 30 | Issue: 6 | Pages: 1165-1166

10.1161/01.str.30.6.1165 | PMID 10356093 Get It